Interestingly, all HER2-positive breast cancer patients exhibiting HER2-loss after neoadjuvant treatment converted to HER2-low-positive phenotype on residual disease, while none of them experienced a complete loss of HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.